

An abstract geometric composition on a dark navy blue background. On the left, a vertical cream-colored rectangle is divided by a thin teal line, with two horizontal teal lines intersecting it at points marked by small teal dots. To the right, a large teal shape is composed of a trapezoid at the bottom and a rectangle on top. A thin white vertical line runs down the center of the teal trapezoid, ending at a small teal circle at its top edge. The word "Japan" is written in a white, sans-serif font, centered horizontally between the cream rectangle and the teal shape.

Japan

Japan

Understanding the applicable framework

JPMA publishes collaboration and transparency guidance. Its May 2022 transparency guideline calls for member companies to establish corresponding company guidelines, making those documents relevant to implementation (Japan Pharmaceutical Manufacturers Association [JPMA], 2022).

Request current company guidelines and distinguish law, JPMA provisions and internal policy. Similar companies may use different documentation or publication formats.

What companies need to understand

JPMA encompasses patient and family support and advocacy groups while leaving aspects of qualification and support selection to company judgement (JPMA, 2022).

Check the actual contracting and payment arrangement, consultation and authority. Seek proportionate alternatives where corporate procedures assume a large staffed organisation.

What patient organisations need to understand

The collaboration framework emphasises ethics, independence and shared understanding; members establish and follow their own guidelines (JPMA, n.d.).

Agree whether personal experience, organisational advice or consultation findings are requested. Explain review and whether activity is independently supported or commissioned.

Funding and information

The transparency guideline covers direct and indirect support and service payments. Explain names, categories and publication before agreement (JPMA, 2022).

The Personal Information Protection Commission explains that special-care-required information such as medical history generally requires prior consent under the applicable framework. Treatment-setting arrangements should not be copied into company interviews without assessment (Personal Information Protection Commission [PPC], n.d.).

Regulatory and access participation

PMDA exchanges with patient groups and provides participation guidance; this does not establish entitlement to every review (Pharmaceuticals and Medical Devices Agency [PMDA], n.d.).

Distinguish development, regulation and reimbursement. Check the route and declarations and retain organisational control.

Practical example and local checks

For advice on trial information, define open decisions, contributors and consultation needs. Explain contracts, payment, disclosure and review. Set information and recording arrangements before meetings and provide feedback afterwards.